TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17061019
Drug: oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral fat load (OIL, soy oil 40 g)
Study: 17061019
Drug: oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral glucose load (OGL, 100 g)
Study: 17061019
Drug: oral fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral fructose load (OFL, 100 g)
Study: 17061019
Drug: iv saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv saline (SAL, 3 ml)
Study: 17061019
Drug: oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral water load (WL, 200 ml)
Study: 12925043
Drug: 50-mg day-1
Normalized name: alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-mg day-1 dose of naltrexone
Study: 12925043
Drug: 50-mg day-1
Normalized name: alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-mg day-1 dose of methadone
Study: 12925043
Drug: 5-mg day-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg day-1 dose of buprenorphine
Study: 11029729
Drug: Fixed lingual
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed lingual arch treatment
Study: 8370294
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion (800 mL of packed red blood cells in 90 mins)
Study: 3720755
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention programme including antihypertensive treatment, dietary advice, and smoking cessation advice applied for 10 years.
Study: 27671517
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection (TUR) + photodynamic therapy (PDT) with alasens
Study: 22224756
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) and standard care
Study: 12762176
Drug: Midazolam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (single intravenous dose)
Study: 9789586
Drug: EA +
Normalized name: Echinacea + bioflavonoid + vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA + drug
Study: 25062420
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: 26333890
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acid supplementation (four 1000-mg supplements daily containing eicosapentaenoic acid 1200 mg plus docosahexaenoic acid 800 mg)
Study: 26333890
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four 1000-mg paraffin oil placebo capsules daily)
Study: 22893563
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg daily
Study: 19186973
Drug: AS-G gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-G gel (ascorbic acid 2-glucoside) applied for 12 weeks
Study: 19186973
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied for 12 weeks
Study: 15557828
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone
Study: 9644707
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration sets changed every 48 hours
Study: 9644707
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration sets changed every 24 hours
Study: 7936368
Drug: Saline enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline enriched water (400 ml at 33 degrees C)
Study: 7936368
Drug: Oligomineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomineral water (400 ml at 33 degrees C)
Study: 7936368
Drug: Saline enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline enriched water (400 ml at 18 degrees C)
Study: 7936368
Drug: Oligomineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomineral water (400 ml at 18 degrees C)
Study: 3914998
Drug: 1 cc
Normalized name: BD Needle SG 1 cc 27g 5/8"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cc of 1% lidocaine
Study: 31696836
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily + LiESWT (2400 shockwaves)
Study: 31696836
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily alone
Study: 20837847
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (20 mg) plus albuterol (oral dose daily for 2 years)
Study: 20837847
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (20 mg) plus placebo (oral dose daily for 2 years)
Study: 18853554
Drug: Composite face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite face task administered at seven orientations
Study: 17379119
Drug: Flurbiprofen 1
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 1 mg . kg(‐1) IV
Study: 17379119
Drug: Placebo (intralipid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intralipid, one mL . kg(‐1))
Study: 9972405
Drug: Tenoxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (40 mg intravenously)
Study: 10792152
Drug: Tenoxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (40 mg intravenously) plus sublingual isosorbide dinitrate (5 mg)
Study: 15215812
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) therapy
Study: 8472522
Drug: ST-679 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-679 (1200 mg)
Study: 2871668
Drug: Polyene fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene fatty acid therapy (linseed oil, fish, and fish oil)
Study: 31132422
Drug: Oleoylethanolamide (OEA)
Normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleoylethanolamide (OEA) supplementation (125 mg daily for 8 weeks)
Study: 31132422
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 mg of starch daily for 8 weeks)
Study: 19516117
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg) injection 1 week before surgery
Study: 19516117
Drug: No bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No bevacizumab injection (Control)
Study: 16984497
Drug: Rabeprazole, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole, 20 mg b.d.
Study: 15558528
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (25 to 200 mg once daily)
Study: 9381772
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (5 intraarticular injections, one injection per week for 5 weeks)
Study: 8359970
Drug: Long-term dietary
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dietary history interview in heavier drinkers (> or = 20 g alcohol per day)
Study: 2877681
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg kg‐1
Study: 2877681
Drug: Edrophonium 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.8 mg kg‐1
Study: 2877681
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antagonist)
Study: 30916447
Drug: Tablet screen
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet screen
Study: 28799458
Drug: Pedometer-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based physical activity program (12 weeks, daily 30-minute walks, individualized daily step targets)
Study: 26679695
Drug: 0.45 g
Normalized name: SODIUM CHLORIDE 0.45 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g nitrate (NIT)
Study: 12501045
Drug: Ketorolac 15
Normalized name: ketorolac 15.75 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 15 mg intravenously every 6 hours starting in the recovery room
Study: 12501045
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution administered every 6 hours starting in the recovery room
Study: 9578010
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day TGB
Study: 9578010
Drug: 36 mg/day
Normalized name: scopolamine 0.3336 MG/Day 72 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg/day TGB
Study: 9578010
Drug: TGB monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGB monotherapy
Study: 9578010
Drug: High-dose TGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TGB (not attaining monotherapy)
Study: 9578010
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not attaining TGB monotherapy
Study: 11220888
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg and 10 mg)
Study: 7636894
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg or 50 mg)
Study: 2526172
Drug: Raclopride 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride 0.1 to 16 mg
Study: 900460
Drug: Enflurane 1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enflurane 1/2 MAC for 1/2 hour (dosage=1/4 MAC hour)
Study: 900460
Drug: Enflurane 1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enflurane 1/2 MAC for 1 MAC hour (dosage=1 MAC hour)
Study: 900460
Drug: Enflurane 1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enflurane 1/2 MAC for 2 MAC hours (dosage=2 MAC hours)
Study: 19958585
Drug: Microsphere formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsphere formulation of azithromycin with ethyl cellulose
Study: 11777261
Drug: Amorolfine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 6 weeks (Group AI‐6)
Study: 11777261
Drug: Amorolfine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 12 weeks (Group AI‐12)
Study: 11777261
Drug: Itraconazole monotherapy
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole monotherapy for 12 weeks (Group I‐12)
Study: 9510275
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous hydration and perioperative monitoring without PACs)
Study: 7801337
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment of the overstimulated autonomic nervous system
Study: 3230152
Drug: CGS 16617
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16617 administered after food
Study: 3230152
Drug: CGS 16617
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 16617 administered in fasted state
Study: 30782930
Drug: ACE inhibitor/angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor/angiotensin receptor blocker-based regimen
Study: 27215274
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (A. paniculata) 170 mg dried extract tablet b.i.d. p.o.
Study: 21128991
Drug: 3TC/ZDV (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC/ZDV (150 mg/300 mg) followed by BILR 355/r (150 mg/100 mg)
Study: 21128991
Drug: BILR 355/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355/r (150 mg/100 mg)
Study: 11803309
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC, approximately 10 microg/kg)
Study: 11803309
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (0.2 mg/kg)
Study: 7006657
Drug: dezocine 10
Normalized name: dezocine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine 10 mg
Study: 7006657
Drug: dezocine 15
Normalized name: dezocine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine 15 mg
Study: 398127
Drug: meperidine 100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 100 mg
Study: 398127
Drug: dezocine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine (both doses)
Study: 31118201
Drug: Chemotherapy (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (more frequent and lower doses)
Study: 31118201
Drug: Antiangiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic agents (lower doses)
Study: 31118201
Drug: Model predictions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model predictions after 12 weeks of treatment
Study: 24987942
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid in each capsule), daily for 4 months
Study: 19021601
Drug: Dapoxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 60 mg as needed or once daily for 9 weeks
Study: 19021601
Drug: Dapoxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 60 mg as needed
Study: 15913621
Drug: Amnioinfusion (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion (1000 mL of warmed sterile saline solution)
Study: 19502264
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional treatment only)
Study: 12459525
Drug: Lithium gluconate
Normalized name: lithium gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium gluconate ointment dosed at 8%
Study: 10604553
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg, once daily (n = 97)
Study: 10604553
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine 200 microg, twice daily (n = 96)
Study: 7722163
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg administered by metered-dose inhaler, twice daily)
Study: 12172464
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (rt-PA)
Study: 25475772
Drug: 0.2% bioadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% bioadhesive chlorhexidine gel
Study: 19473538
Drug: External shock
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External shock wave therapy (ESWT) combined with standard care
Study: 17243107
Drug: Multi-component smoking
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component smoking cessation intervention (nurse led behavioral/empowerment counseling, nicotine replacement therapy, community health workers)
Study: 10193877
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0.75 pmol x kg(‐1) min(‐1))
Study: 2376386
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution (5%) applied topically, 2 drops
Study: 2376386
Drug: NaCl solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl solution, 2 drops
Study: 22326237
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine (up to 16 mg/24h)
Study: 20386063
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (music group, n = 20)
Study: 18316526
Drug: Maribavir alone
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir alone (400 mg)
Study: 18316526
Drug: Maribavir plus
Normalized name: maribavir
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir plus ketoconazole (400 mg)
Study: 16010245
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) administered during donor operation (IV & Portal flush)
Study: 10910310
Drug: Ranitidine hydrochloride,
Normalized name: Ranitidine Hydrochloride, 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine hydrochloride, 150 mg twice daily
Study: 12562445
Drug: Lansoprazole, 15
Normalized name: Lansoprazole, 15 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 15 mg once daily
Study: 9055014
Drug: Topical squaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical squaric acid dibutylester (SADBE) applied weekly for 20 weeks after sensitization with 2% SADBE in acetone
Study: 9055014
Drug: Topical squaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical squaric acid dibutylester (SADBE)
Study: 1647443
Drug: Intravenous flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flumazenil (3 mg)
Study: 1647443
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (10 mg)
Study: 6384072
Drug: Pindolol (20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (20.0 +/- 3.13 mg/d)
Study: 6384072
Drug: Propranolol (125.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (125.0 +/- 19.17 mg/d)
Study: 29119300
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities (including antibiotics, IVIG, psychiatric medications, cognitive behavioral therapy)
Study: 26700848
Drug: Chronic maternal
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic maternal hyperoxygenation (CMH) therapy, ≥ 8 hours daily from enrollment until delivery.
Study: 26700848
Drug: Chronic maternal
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic maternal hyperoxygenation (CMH) therapy, > 9 hours daily (n=6).
Study: 20556802
Drug: Furosemide, 40
Normalized name: Furosemide, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 40 mg intravenous bolus
Study: 20556802
Drug: Nesiritide, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide, 2 microg/kg intravenous bolus followed by a 0.01 microg/kg/min infusion for 6 hours
Study: 18018468
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy (Group B)
Study: 16361986
Drug: Current treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatments for mania (specific interventions not detailed)
Study: 11915580
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 2.5 mg/24 h transdermal patches
Study: 11915580
Drug: Diclofenac (DCF)
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac (DCF) 50 mg per os
Study: 10080605
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 10 mg every 4 weeks
Study: 10080605
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 20 mg every 4 weeks
Study: 10080605
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 30 mg every 4 weeks
Study: 7747843
Drug: Rectal sodium
Normalized name: Rectal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal sodium diclofenac 100 mg
Study: 8467273
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment alone (Group C)
Study: 31394282
Drug: Supervised progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised progressive resistance training (36 sessions, 1 hour each, 3 times weekly for 12 weeks)
Study: 31394282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no change in daily activity level)
Study: 19156568
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 microg as an intravenous bolus) with naloxone (2 mg bolus followed by 1.6 mg/h infusion)
Study: 19156568
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 microg as an intravenous bolus) without naloxone
Study: 11074396
Drug: ss2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ss2-agonist
Study: 11074396
Drug: ss2-agonist and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ss2-agonist and ICS
Study: 9512845
Drug: 0.54% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.54% hyperbaric lidocaine (48 mg)
Study: 9512845
Drug: 0.3% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% hyperbaric lidocaine (72 mg)
Study: 7836703
Drug: High prolactin
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High prolactin release (delta prolactin > 1000 mu u/ml, n = 11)
Study: 7836703
Drug: Low prolactin
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low prolactin release (delta prolactin < 1000 mu u/ml, n = 8)
Study: 2975199
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dapsone daily for 16 weeks
Study: 2975199
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg 13‐cis retinoic acid daily for 16 weeks